Supplementary Figure 2B from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Autor:	Hagop M. Kantarjian, Elihu H. Estey, L. Austin Doyle, Steven M. Kornblau, Keith A. Baggerly, Wenbin Liu, Michael Andreeff, Jan A. Burger, LaKiesha Debose, Hongbo Lu, Jennie B. Feliu, Peter P. Ruvolo, Tapan M. Kadia, Xuelin Huang, Gautam Borthakur, Zhihong Zeng, Elias J. Jabbour, Stefan H. Faderl, Roland B. Walter, Marina Y. Konopleva
Rok vydání:	2023
DOI:	10.1158/1078-0432.22450362.v1
Popis:	PDF file - 60KB, MK-2206 promotes accumulation of OCI-AML3 cells in the G1 phase of the cell cycle.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16c9996580deef2cab1d6a682f076c58 https://doi.org/10.1158/1078-0432.22450362.v1 Zobrazit plný text záznamu